Biocon Limited announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Zentiva. Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
309.6 INR | +0.13% | -1.68% | +24.03% |
May. 24 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
May. 24 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.03% | 4.42B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.61% | 21.96B | |
-9.19% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K